Inclusion Criteria for Neoadjuvant Therapy:

          -  Pathologically documented NSCLC: Stage IIA, IIB, IIIA, or selected IIIB, including
             T3N2, or T4 (by size criteria, not by mediastinal invasion) NSCLC (based on the 8th
             edition of the American Joint Committee on Cancer [AJCC] Non-Small Cell Lung Cancer
             Staging system

          -  Molecular testing results from CLIA-certified laboratories and showing at least one of
             the following abnormalities: ALK fusion, ROS1 fusion, NTRK1/2/3 fusion; BRAF V600
             mutation; RET fusion

          -  Measurable disease, as defined by RECIST v1.1

          -  Evaluated by the attending surgeon prior to study enrollment to verify that the
             primary tumor and any involved lymph nodes are technically completely resectable and
             verify that the participant is medically operable

          -  Adequate pulmonary function to be eligible for surgical resection with curative intent

          -  Adequate cardiac function to be eligible for surgical resection with curative intent

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Male participants must be willing to use acceptable methods of contraception

          -  Female participants of childbearing potential must agree to use acceptable methods of
             contraception

        Inclusion Criteria for Adjuvant Therapy

          -  Participants whose tumors lack radiographic progression

          -  ECOG Performance Status of 0 or 1

          -  Adequate hematologic and end-organ function

        Exclusion Criteria

          -  NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by
             virtue of N3 disease

          -  Any prior therapy for lung cancer, including chemotherapy, targeted therapy,
             immunotherapy, or radiotherapy, within 2 years

          -  Participants with prior lung cancer that have been in remission for <2 years with the
             exception of minimally invasive adenocarcinoma or incidental typical carcinoid tumors

          -  Major surgical procedure within 28 days prior to Cycle 1, Day 1

          -  Participants known to be positive for HIV are excluded if they meet any of the
             following criteria: CD4+ T-cell count of <350 cells/microliters; detectable HIV viral
             load; history of an opportunistic infection within the past 12 months; on stable
             antiretroviral therapy for <4 weeks

          -  Severe infection within 4 weeks prior to initiation of study treatment, including but
             not limited to hospitalization for complications of infections, or any active
             infection that, in the opinion of the investigator, could impact participant safety

          -  Pregnant or lactating, or intending to become pregnant during the study